The Kemp Laboratory of Functional Precision Medicine seeks to identify the next generation of targeted anticancer agents. We use a combination of high throughput functional genomic and small molecule screens, and genomic analysis to identify new cancer drug targets, anchored to genetic biomarkers. A range of isogenic and patient derived tumor models is used to discover and validate targets for several cancer types in great need of effective targeted therapies including head and neck squamous cell carcinoma, ovarian cancer, breast cancer, pancreatic cancer and others. Molecular biological and in vivo models are used to determine mechanism of cancer cell death or tumor regression following target inhibition.
Dr. Kemp is a member of the Cancer Target Discovery and Development (CTD2) Network working to bridge the knowledge gap between cancer genomics and precision oncology by mining and functionally validating high-throughput, high-content genomic data and translating the finding to the bedside.
CTD2 Network comprised of 12-National Cancer Institute Office of Cancer Genetics-supported research teams, called Centers. The Centers work independentaly and collaboratively. Network Centers utilize a combination of state-of-the-art high throughput informatic and experimental approaches to functionally validate discoveries from genomic studies and advance them toward precision oncology. They share data and resources, such as analytical tools and reagents, across the Network and with the research community.